TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 30

Author

Pharma Journalist 8887 posts 0 comments

FDA Issues Complete Response Letter for Aquestive Allergy Film

Feb 3, 2026
Aquestive Therapeutics said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its New Drug Application seeking approval of Anaphylm, an…
Read More...

Genentech Licenses SanegeneBio RNAi Therapy in $1.5B Deal

Feb 3, 2026
SanegeneBio has entered a global licensing agreement with Genentech, part of the Roche Group, granting the pharmaceutical company exclusive worldwide rights to develop and commercialize…
Read More...

FDA Grants Breakthrough Status to Immix AL Amyloidosis Therapy

Jan 30, 2026
Immix Biopharma, Inc., a clinical-stage biotechnology company focused on developing therapies for difficult-to-treat diseases, has received a major regulatory boost after the U.S. Food…
Read More...

WuXi Biologics, Sinorda Partner on Bispecific Antibody for IBD

Jan 30, 2026
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and manufacturing of SND006, a novel bispecific antibody being developed…
Read More...

Recordati, Moderna Partner on mRNA Therapy for Rare Metabolic Disease

Jan 30, 2026
Recordati has entered into a global collaboration and licensing agreement with Moderna to develop and commercialize mRNA-3927, an investigational mRNA-based therapy for the treatment of…
Read More...

IQVIA, Boehringer Ingelheim Partner on Global Commercial Data Transformation

Jan 30, 2026
IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic long-term collaboration with Boehringer Ingelheim…
Read More...

FDA Grants Breakthrough Status to Biogen’s Lupus Skin Therapy

Jan 30, 2026
The Lupus Research Alliance has welcomed the U.S. Food and Drug Administration’s decision to grant Breakthrough Therapy designation to litifilimab (BIIB059), an investigational…
Read More...

Sensorion Raises €60m to Advance Gene Therapies for Hearing Loss

Jan 30, 2026
Sensorion, a clinical-stage biotechnology company focused on developing novel treatments to restore, treat, and prevent hearing loss, has announced a €60 million capital raise to…
Read More...

AstraZeneca, CSPC Partner on Next-Generation Obesity Therapies

Jan 30, 2026
AstraZeneca has strengthened its weight management and metabolic disease pipeline through a new strategic collaboration with CSPC Pharmaceuticals, targeting the development of multiple…
Read More...

AstraZeneca Pledges $15bn to Expand China R&D, Manufacturing

Jan 30, 2026
AstraZeneca has announced a landmark $15 billion investment in China through 2030, significantly expanding its research, development, and manufacturing capabilities as part of its…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.